$ROIV News

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow

Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials

Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results

Why Is Roivant Sciences Stock Surging Wednesday?

Roivant Sciences stock surges on positive uveitis trial data

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years

Wolfe Research Downgrades Roivant Sciences to Peer Perform

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call

Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?

Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51

Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD - Slideshow